KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Castle Biosciences (CSTL) Inventory (2018 - 2026)

Castle Biosciences' Inventory history spans 8 years, with the latest figure at $10.3 million for Q4 2025.

  • On a quarterly basis, Inventory rose 26.05% to $10.3 million in Q4 2025 year-over-year; TTM through Dec 2025 was $10.3 million, a 26.05% increase, with the full-year FY2025 number at $10.3 million, up 26.05% from a year prior.
  • Inventory hit $10.3 million in Q4 2025 for Castle Biosciences, up from $8.6 million in the prior quarter.
  • Over the last five years, Inventory for CSTL hit a ceiling of $10.3 million in Q4 2025 and a floor of $2.0 million in Q4 2021.
  • Historically, Inventory has averaged $5.6 million across 5 years, with a median of $5.9 million in 2023.
  • Biggest five-year swings in Inventory: skyrocketed 99.55% in 2023 and later decreased 10.41% in 2025.
  • Tracing CSTL's Inventory over 5 years: stood at $2.0 million in 2021, then skyrocketed by 96.93% to $4.0 million in 2022, then skyrocketed by 99.55% to $7.9 million in 2023, then rose by 2.43% to $8.1 million in 2024, then increased by 26.05% to $10.3 million in 2025.
  • Business Quant data shows Inventory for CSTL at $10.3 million in Q4 2025, $8.6 million in Q3 2025, and $8.4 million in Q2 2025.